CBD Cigarettes Instead of Normal Cigarettes as Innovative Treatment for Schizophrenia
NCT ID: NCT04700930
Last Updated: 2021-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
31 participants
INTERVENTIONAL
2018-10-04
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Reduction of enforcement measures, improved acute treatment, harm reduction, and improvement of psychotic symptoms
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
NCT01213524
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
NCT00307203
The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study
NCT00302432
Cannabidiol Treatment in Patients With Early Psychosis
NCT02504151
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
NCT04605393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CBD
Patients receive CBD cigarettes additionally to standard psychiatric care including neuroleptic medication
CBD-Cigarettes
CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
Non-CBD
Patients recieve standard psychiatric care including neuroleptic medication
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CBD-Cigarettes
CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PANNS \> 21,
* Tobacco-smokers
* inpatient status
* within age 18 - 65 years
* German-speaking
Exclusion Criteria
* non-smokers
* organic psychotic diseases
* breast feeding
* pregnancy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Psychiatric Hospital of the University of Basel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Stefan Borgwardt
Principle Investigator, Clinical Professor, Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Undine Lang, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitäre Psychiatrische Kliniken
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kock P, Lang E, Trulley VN, Dechent F, Mercer-Chalmers-Bender K, Frei P, Huber C, Borgwardt S. Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study. Front Psychiatry. 2021 Nov 4;12:736822. doi: 10.3389/fpsyt.2021.736822. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-01111
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.